Trial Profile
Drug Use Investigation of Riociguat for Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms JPMS-PAH
- Sponsors Bayer
- 26 Jan 2024 Status changed from recruiting to completed.
- 21 Oct 2022 Planned primary completion date changed from 30 Sep 2022 to 31 Mar 2023.
- 02 Apr 2018 Planned primary completion date changed from 31 Mar 2023 to 30 Sep 2022.